VIMIAN Stock Overview
Vimian Group AB (publ) engages in the animal health business worldwide.
Vimian Group AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr42.80|
|52 Week High||kr123.40|
|52 Week Low||kr37.26|
|1 Month Change||2.44%|
|3 Month Change||-21.68%|
|1 Year Change||-58.45%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-47.10%|
Recent News & Updates
We Like These Underlying Return On Capital Trends At Vimian Group (STO:VIMIAN)
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 34% Discount?
Does the May share price for Vimian Group AB (publ) ( STO:VIMIAN ) reflect what it's really worth? Today, we will...
|VIMIAN||SE Medical Equipment||SE Market|
Return vs Industry: VIMIAN underperformed the Swedish Medical Equipment industry which returned -44.8% over the past year.
Return vs Market: VIMIAN underperformed the Swedish Market which returned -21.8% over the past year.
|VIMIAN Average Weekly Movement||8.8%|
|Medical Equipment Industry Average Movement||7.6%|
|Market Average Movement||7.2%|
|10% most volatile stocks in SE Market||12.6%|
|10% least volatile stocks in SE Market||4.5%|
Stable Share Price: VIMIAN is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VIMIAN's weekly volatility (9%) has been stable over the past year.
About the Company
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
|VIMIAN fundamental statistics|
Is VIMIAN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VIMIAN income statement (TTM)|
|Cost of Revenue||€59.14m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Nov 16, 2022
|Earnings per share (EPS)||0.011|
|Net Profit Margin||2.07%|
How did VIMIAN perform over the long term?See historical performance and comparison